News

The recommendation by the CHMP of the EMA for approval of ruxolitinib to treat of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis

The RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia utilized Tekmira’s lipid nanoparticle (LNP) technology. Tekmira president and CEO Mark Murray said the new data from

ACY-1215T is at present being investigated in human trials to treat multiple myeloma. Acetylon chief executive officer Walter Ogier said, "Given the widespread interest in the development of

The Sevikar, a fixed dose combination of olmesartan medoxomil and amlodipine besylate tablets, is likely to be included on the national lists of compensated drugs. The combination will

The patent covers a core element of Rosetta’s microRNA technology in the development of cancer therapeutics associated with p53-negative cancers. Rosetta Genomics president and chief executive officer Kenneth

Adimab also announced the achievement of technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech. Adimab CEO Tillman Gerngross said, "We are now expanding our

The filing of an investigational new drug application with the FDA for a monoclonal antibody that was optimized using Xencor’s XmAb antibody technology prompted the milestone payment. Xencor

Daclatasvir is an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor. In the Phase II open-label clinical trial (AI447-017), patients were divided into two

The single-blind, randomized trial is expected to enrol 72 obese patients, with a body mass index between 30 and 35kg/m². The primary objective of the placebo-controlled trial is